In addition, these current factorial clinical trials regarding cardiovascular disease mainly focused on statin but not proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for lipid lowering, and β-blockers (BBs) for antihypertension were rarely studied. Here, PCSK9 is linked to cardiovascular disorder.